RF Acquisition Corp. shareholders overwhelmingly approved the business combination with Nanyang Biologics, clearing the path for a Nasdaq listing. This approval, despite significant redemption requests, has led to a massive surge in RFAI's stock price, indicating strong market enthusiasm for the combined entity.
RF Acquisition Corp. (RFAI) shareholders have given the green light to merge with Nanyang Biologics, an AI-driven drug discovery firm. This approval is a critical step for the SPAC, allowing the combined entity, NYB Holdings Limited, to proceed with its Nasdaq listing. The market has reacted extremely positively, with RFAI shares skyrocketing over 260% in premarket trading, indicating high investor confidence in the future prospects of the merged company, particularly given Nanyang Biologics' focus on AI in drug discovery. While there were significant redemption requests, the overwhelming approval of the merger and related proposals signals a strong path forward, creating a short-term opportunity for traders capitalizing on the momentum and a long-term opportunity for investors betting on the success of the new biotech venture.